Application of the CardioCel bovine pericardial patch – a preliminary report

Introduction

Pericardial patches made from animal tissue have a wide range of applications in various fields of surgery including vascular and general surgery, urology, and cardiac surgery. Some noteworthy applications of pericardial patches in cardiac surgery include the reconstruction of the aorta and pulmonary vessels, closure of interatrial defects, closure of interventricular defects, and reconstruction of atrioventricular valves [1–3]. Their advantages include the ease with which they can be obtained and used as well as the fact that they are associated with less intraoperative bleeding from the suture line in comparison with artificial materials [1, 4, 5]. The disadvantages include the development of secondary stenosis at the suture site (resulting from fibrosis and calcification), the possibility of aneurysm development, and, often, high prices of the products [5]. Many implants are available on the market: biointegral pericardial patches, the bovine collagen membrane Tutopatch, and the equine pericardial patch from Edwards Lifesciences. One of the newest products on the market is the bovine pericardial patch CardioCel, distinguished from the other available products by the fact that glutaraldehyde is not used during its processing.

Aim

The aim of this report is to provide preliminary analysis of the effects of the CardioCel pericardial patch in pediatric patients undergoing congenital heart defect correction requiring the use of the implant.

Material and methods

The study included 8 patients who underwent repair of congenital heart defects under extracorporeal circulation and were implanted with CardioCel pericardial patches during the period between January 2015 and February 2016. The age of the patients ranged from 10 days to 14 years. The patients underwent three types of procedures: aortic arch reconstruction, repair of supravalvular aortic stenosis, and pulmonary artery reconstruction. The demographic details of the patients and the types of procedures are presented in Table I.
The study employed data originating from the patients’ medical records, operative protocols, and the local hospital database, as well as results of echocardiography, angiography, and computed tomography (angio-CT).

The patch

Intraoperatively, the patch required no further preparation. After being taken out of the container, it was ready to be used.
Its mechanical endurance was found to be satisfactory: the sutures held without rupturing the graft, and the implant’s elasticity facilitated optimal adaptation of the patch to the native tissue. No significant bleeding from the suture site was observed during the procedures. Perioperatively, there were no clinical or laboratory signs of infection that could be associated with the patch implantation.

Results

There was no in-hospital mortality; all the patients included in the study were alive at the conclusion of the follow-up. The length of hospital stay ranged from 8 to 58 days (median: 15 days). The observed complications included: pneumonia in 2 patients, vocal cord paralysis in 2 patients, and paralysis of the left diaphragmatic dome in 1 patient (which necessitated a plication procedure during the same hospitalization).
The postoperative follow-up lasted from 14 to 219 days (median: 58 days). During this time, no aneurysms, patch thickening, or calcification at the suture site occurred in any of the patients. There were no clinical or laboratory signs of infection that could be associated with the patch implantation.
In 2 patients, stenosis was observed at the suture site. In the patient with aortic arch hypoplasia, atrioventricular septal defect, and Down’s syndrome, the stenosis at the suture site was observed from the first days after the procedure performed to widen the aortic arch. Follow-up transthoracic echocardiography revealed no signs of coarctation at the suture site; the mean flow velocity in the aortic arch was 3.0 m/s, and the flow in the abdominal aorta corresponded with the arterial flow. In the patient who underwent repair of supravalvular stenosis of the ascending aorta and reconstruction of the pulmonary trunk and right pulmonary artery, increasing stenosis is observed at both suture sites (MVF 4.5 m/s in the ascending aorta and MVF 3.3 m/s in the pulmonary vessels). No significant clinical consequences of the stenosis were observed in either of the patients; both remain under out-patient observation.

Discussion

The use of bovine pericardium has many applications in both adult and pediatric cardiac surgery [1–4]. Many cardiac surgeons use it, appreciating the wide selection of implants and their potential advantages. Currently, a search is ongoing for a material that will have optimal surgical properties and will limit the occurrence of complications such as secondary stenosis, intraoperative bleeding, infections at the suture site, and aneurysm development [5–7].
This report presents preliminary experiences with the use of a next-generation acellular bovine pericardial patch – CardioCel. According to the manufacturer, the patch can be used for intracardiac defect corrections, atrioventricular valve reconstruction, or vascular repair. Neethling et al. demonstrated satisfactory results of using the patch for correcting intracardiac defects and performing vascular reconstruction in a group of 30 children [8]. Favorable properties of the patch as a potential material for valve reconstructions have been demonstrated in an animal model [9]. Mazzitelli et al. were the first to report the use of CardioCel for reconstructing the aortic valve in 3 pediatric patients, with good results [10]. The abovementioned reports present successful preliminary results, but are limited by small sample sizes and short follow-up periods.

Conclusions

In our material, the patch was employed to reconstruct the aorta and pulmonary arteries. Satisfactory properties of the patch were observed intraoperatively. The use of the patch was associated with positive results according to the preliminary observations made at our center; however, precise analysis requires studies on larger patient samples and with longer periods of follow-up.

Disclosure

Authors report no conflict of interest.

References

1. Us MH, Sungun M, Sanioglu S, Pocan S, Cebeci BS, Ogus T, Ucak A, Guler A. A retrospective comparison of bovine pericardium and polytetrafluoroethylene patch for closure of ventricular septal defects. J Int Med Res 2004; 32: 218-221.
2. David TE. The use of pericardium in acquired heart disease: a review article. J Heart Valve Dis 1998; 7: 13-18.
3. Yaliniz H, Salih OK, Atalay A, Keklik V, Gocen U, Topcuoglu MS, Guzel Y, Basturk Y, Aslan M, Erdem S, Poyrazoglu H. Short- and mid-term results of xenograft-bovine pericardial patch in the repair of intracardiac defects: final results of a single-centre study. Cardiol Young 2014; 24: 510-514.
4. Crawford FA Jr, Sade RM, Spinale F. Bovine pericardium for correction of congenital heart defects. Ann Thorac Surg 1986; 41: 602-605.
5. Li X, Guo Y, Ziegler KR, Model LS, Eghbalieh SD, Brenes RA, Kim ST, Shu C, Dardik A. Current usage and future directions for the bovine pericardial patch. Ann Vasc Surg 2011; 25: 561-568.
6. Chang Y, Lai PH, Wang CC, Chen SC, Chang WC, Sung HW. Mesothelium regeneration on acellular bovine pericardia loaded with an angiogenic agent (ginsenoside Rg1) successfully reduces postsurgical pericardial adhesions. J Thorac Cardiovasc Surg 2006; 132: 867-874.
7. Santibanez-Salgado JA, Olmos-Zuniga JR, Perez-Lopez M, Aboitiz-Rivera C, Gaxiola-Gaxiola M, Jasso-Victoria R, Sotres-Vega A, Baltazares-Lipp M, Pérez-Covarrubias D, Villalba-Caloca J. Lyophilized glutaraldehyde-preserved bovine pericardium for experimental atrial septal defect closure. Eur Cell Mater 2010; 19: 158-165.
8. Neethling WM, Strange G, Firth L, Smit FE. Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated Cardi^oCel(R) patch. Interact Cardiovasc Thorac Surg 2013; 17: 698-702.
9. Brizard CP, Brink J, Horton SB, Edwards GA, Galati JC, Neethling WM. New engineering treatment of bovine pericardium confers outstanding resistance to calcification in mitral and pulmonary implantations in a juvenile sheep model. J Thorac Cardiovasc Surg 2014; 148: 3194-3201.
10. Mazzitelli D, Nobauer C, Rankin JS, Vogt M, Lange R, Schreiber C. Complete aortic valve Cusp replacement in the pediatric population using tissue-engineered bovine pericardium. Ann Thorac Surg 2015; 100: 1923-1925.